Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Stock Report

| More

Suven Life Sciences announces Top-Line Results of SUVN-502 (Masupirdine) Phase 2A Study in Patients with Moderate Alzheimer's Disease (AD)

Posted On: 2019-11-30 16:58:51

SUVN-502 did not meet the pre-specified primary endpoint

Meaningful improvements and potential beneficial effects on cognitive function, behavioral and neuropsychiatric end points were emerged based on subgroup analyses.

SUVN-502 was safe and well tolerated with no significant adverse events

Suven Life Sciences announces top-line results from its Phase 2A proof of concept study evaluating the efficacy, safety and tolerability of Masupirdine (SUVN-502). The first of its kind trial which focused on advanced stage AD patients (moderate AD) who are currently treated with standard of care Donepezil and Memantine. The unique triple-therapy (Masupirdine+ Donepezil+ Memantine) design was based on efficacy results in pre-clinical cognition models in which masupirdine enhances the effects of combined treatment with Donepezil and Memantine.

The primary efficacy endpoint of the trial is change from baseline to Week 26 in ADAS-Cog 11 score. The secondary outcome measures are MMSE, CDR-SB, ADCS-ADL, NPI, C-SDD, safety and tolerability assessment.

Findings of this Phase 2A study:

- Masupirdine (SUVN-502) is safe and well tolerated without significant adverse events.

- Triple therapy of Masupirdine (SUVN-502) with Donepezil and Memantine proof of concept phase 2 study missed its pre-specified primary endpoint.

- Subgroup analyses on cognition, function, behavioral, neuropsychiatric inventory and secondary endpoints revealed interesting, statistically significant and potentially beneficial data sets.

- Potential beneficial effects and statistically significant results with Masupirdine treated groups on cognition emerged upon considering combinations of Patients Age, Memantine regimen, Memantine plasma concentration, Memantine treatment duration and Alzheimer's disease duration.

- Sub-population of Masupirdine treated patients showed significant improvement and statistically significant reduction in the behavioral symptoms in the domains of agitation / aggression and delusions /hallucination as assessed by the NPI subscale scores.

- Detailed study outcomes of the above findings will be presented through one oral and six poster presentations at Clinical Trials on Alzheimer's Disease (CTAD) being held at San Diego from 4th - 7th December 2019.

We are very disappointed with the outcome of this trial but the findings present an important step forward in further exploration of the potential therapeutic effects of Masupirdine (SUVN-502) in Alzheimer's Disease (AD) and Behavioral & Psychological Symptoms in Dementia (BPSD). We will work with regulators and potential partnering companies in the design and conduct of future studies for further exploration of the potential of Masupirdine (SUVN-502) says Venkat Jasti, CEO of Suven.

Shares of SUVEN LIFE SCIENCES LTD. was last trading in BSE at Rs.314.05 as compared to the previous close of Rs. 312.75. The total number of shares traded during the day was 52597 in over 1718 trades.

The stock hit an intraday high of Rs. 317.6 and intraday low of 309.85. The net turnover during the day was Rs. 16529894.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Motherson Sumi Systems Ltd board to consider interim dividend on Feb 28, 2020

NLC India Ltd updates on arbitration award

Lasa Supergenerics Ltd to acquire Harishree Aromatics and Chemicals Pvt Ltd

KSB Ltd launches FGD KWPK

Pee Cee Cosma Sope Ltd board declares interim dividend of Rs. 3 for FY2019-20

Sacheta Metals Ltd declares interim dividend of Rs. 0.20 for FY20

Alufluoride Ltd board declares interim dividend of Rs. 2 for 2019-20

Biocon's Insulin Manufacturing Facility in Malaysia gets 3 obsevations from U.S. FDA (PAI) inspection

PNB Housing Finance Limited's ratings downgraded to 'CRISIL AA/FAA+ / Stable'

UPL Corporation Ltd prices $400 million bonds

Dilip Buildcon Ltd executes EPC agreement with AAI for project in Gujarat

USFDA conclude inspections at Solara's Puducherry and Mangalore facility with zero 483 observations

Hind Rectifiers Limited gets 26930 Sq Mtrs land on lease from MIDC

Vesuvius India Ltd Board recommends Dividend of Rs. 8.74

M&M to sell clean energy subsidiaries to CLP India Pvt. Ltd.

Apollo Tyres Ltd board to consider preferential issue, interim dividend

Alkem's manufacturing facility at Baddi receives 2 observations from USFDA

Gulshan Polyols Ltd board declares interim dividend of Rs. 0.70

Vesuvius India Ltd Q4 PAT up at Rs. 22.70 crore

Strides Consumer announces its strategic entry into Northern India

Sahyadri Industries Ltd board declares interim dividend of Rs. 2.5 for FY2019-20

Anuh Pharma Ltd board declares interim dividend of Rs. 2.75 for FY20

PVR Ltd Opens Multiplex at Nilamber Triumph Mall in Vadodara, Gujarat

Chemcrux Enterprises Ltd Board to consider Interim Dividend on Feb 27, 2020

Muthoot Finance Ltd raises USD 550 million from International Bond Markets

TCS UK Named in The Sunday Times List of Best Big Companies to Work For 2020

USFDA reverses status of Aurobindo Pharma Ltd's general injectable formulation unit

Gujarat Alkalies and Chemicals Ltd commissions expanded capacity of Stable Bleaching Powder Plant at Dahej

Bajaj Holdings & Investment Ltd Board declares Interim Dividend of Rs. 40 for FY2019-20

Bajaj Auto Ltd Board declares Interim Dividend of Rs. 120 for FY2020

Bajaj Finserv Ltd Board declares Interim Dividend of Rs. 5 for FY20

Bajaj Finance Ltd Board declares Interim Dividend of Rs. 10 for 2019-20

Maharashtra Scooters Ltd Board declares Interim Dividend of Rs. 50

ICICI Lombard and realme Pay enter into strategic association for providing screen protection cover for realme phones

Ambuja Cements Ltd Q4 CY2019 consolidated PAT lower at Rs. 591.54 crore

ICRA revises long term rating of Indiabulls Housing Finance Limited

GMR Infrastructure Limited announces Strategic Partnership with Groupe ADP for Airports Business

Muthoot Finance Ltd announces pricing of USD 550 million 4.40% notes

UFO Moviez India Ltd board to consider interim dividend on Feb 27, 2020

Dr. Reddy's Laboratories Ltd receives EIR for Duvvada Formulations Plant

Dhanlaxmi Bank Ltd receives RBI nod for appointment of MD & CEO

Sharda Cropchem Ltd Board to consider Second Interim Dividend for FY20

Ambuja Cements Ltd Board recommends Dividend of Rs. 1.50 for CY2019

Plastiblends India Ltd board to consider interim dividend on Feb 25, 2020

Cyient Organizes Blood Donation Drive at its Hyderabad Campus

TCS Named as One of the Fortune Best Big Companies to Work For™ in 2020

India Infoline Finance Ltd raises $400 million

Ambuja Cements Limited appoints Mr. Neeraj Akhoury as new MD and CEO

Garware Technical Fibres Ltd to dispose business undertaking in USA

AstraZeneca Pharma India Ltd launches FDC of Dapagliflozin 10mg + Saxagliptin 5mg film coated tablets (QTERN®)







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019